Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
The MARIPOSA update series explores the evolving treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC), highlighting how the amivantamab plus lazertinib combination outperforms osimertinib as a first-line therapy. Through updated analyses from ESMO 2025, it demonstrates that this dual EGFR-MET targeting approach significantly reduces mechanisms of acquired resistance—especially MET amplification and secondary EGFR mutations—resulting in longer progression-free and overall survival. The findings reinforce the biologic rationale for early combination therapy, reduced mutational heterogeneity, and the potential to reshape long-term outcomes for patients with EGFR-mutant NSCLC

Featured Video